Christopher Biggins has revealed he's using the medication Mounjaro and has credited it for his dramatic transformation as he ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Eli Lilly & Novo Nordisk target cash-pay customers in the GLP-1 weight loss market with $499 monthly offers. Read more here.

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Novo Nordisk stock was jumping Monday after the company said late Friday that its weight-loss medicine Wegovy had been approved to treat a serious form of liver disease. It’s a welcome boost for the ...

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, at a cash price of $499 per month.

In the first 24 hours after Lilly's announcement, Ozempic sales rose by 400 per cent, according to weight loss jab provider CheqUp.